Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "Outcome measures" patented technology

Outcome measure. Determination and evaluation of the results of an activity, plan, process, or program and their comparison with the intended or projected results.

Visually directed human-computer interaction for medical applications

InactiveUS20110270123A1Faster and intuitive human-computer inputFaster and more intuitive human-computer inputDiagnostic recording/measuringSensorsGuidelineApplication software
The present invention relates to a method and apparatus of utilizing an eye detection apparatus in a medical application, which includes calibrating the eye detection apparatus to a user; performing a predetermined set of visual and cognitive steps using the eye detection apparatus; determining a visual profile of a workflow of the user; creating a user-specific database to create an automated visual display protocol of the workflow; storing eye-tracking commands for individual user navigation and computer interactions; storing context-specific medical application eye-tracking commands, in a database; performing the medical application using the eye-tracking commands; and storing eye-tracking data and results of an analysis of data from performance of the medical application, in the database. The method includes performing an analysis of the database for determining best practice guidelines based on clinical outcome measures.
Owner:REINER BRUCE

Systems and methods for using and constructing user-interest sensitive indicators of search results

Techniques are provided to construct and use user-interest sensitive indicators of search results. A set of documents is determined based on one or more search terms. Passages within each selected document are identified based on the search terms. Condensation transformations applied to the passages to preferentially retain elements of the passage based on the search terms and user interest information. The resultant indicator is provides a user-interest sensitive signal of the meaning of the passage.
Owner:PALO ALTO RES CENT INC

Method for tracking and assessing program participation

Disclosed is a computerized decision support system and method for a) tracking participation within programs, b) capturing participant's participation activity and assessment information in a format that can be easily analyzed and c) distilling the participation and assessment data into useful management and evaluation information. The repository of longitudinal data can be analyzed and reported for case-management and program-evaluation purposes. An assessment module enables analyzable assessment instruments to be custom-defined by the system user, e.g. a program manager. The customized assessment instrument is used to provide answer-restricted questions during an assessment interview, enabling virtually any data item to be tracked historically. The system captures date/time-stamped participation information at various levels of detail and stores this information in a way that can be easily retrieved and analyzed for program and participant-focused analysis. A set of industry-standard participation events can be tracked, with supporting detail, as well as less-data-intensive ad hoc user-defined activities. The data model underlying the system, and the implementation of this model within a relational database system, provides a great degree of flexibility, adaptability and efficient navigation through the database for analysis and reporting. Though numerous program-evaluation reports are provided, a set of intermediary aggregations of data is also available for efficient evaluation of additional program outcome measures.
Owner:LOVEGREN VICTORIA M

Retrospective retrofitting method to generate a continuous glucose concentration profile by exploiting continuous glucose monitoring sensor data and blood glucose measurements

Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycaemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a “retrofitting” algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting algorithm produces an improved “retrofitted” quasi-continuous glucose concentration signal that is better (in terms of both accuracy and precision) than the CGM trace originally measured by the sensor. In clinical trials, the so-obtained retrofitted traces can be used to calculate solid outcome measures, avoiding the need of increasing the data collection burden at the patient level.
Owner:DEXCOM

Systems for clinical trials

InactiveUS20100280975A1Medical simulationData processing applicationsBaseline IndicatorTreatment Arm
The invention provides methods and systems for assessing the efficacy of a pharmaceutical which is putatively disease modifying of a cognitive disorder, for use in the treatment or prophylaxis of that cognitive disorder, the method comprising the steps of: (1) stratifying a subject group into at least 2 sub-groups according to a baseline indicator of likely disease progression, (2) treating members of each subject group with the pharmaceutical for a treatment time frame, (3) deriving psychometric and optionally physiological outcome measures for each treated patient group, (4) comparing the outcomes at (3) with a comparator arm of said sub-groups which is optionally a placebo or minimal efficacy comparator arm, (5) using the comparison in (4) to derive an efficacy measure for the pharmaceutical. The methods and systems of the invention address problems such as low rate of decline over the treatment time-frame of patients who have mild-disease severity at baseline and biased withdrawal, particularly in the placebo / comparator treatment arm.
Owner:WISTA LAB LTD

City development level calculation method

InactiveCN106845749AAvoid complex and bulky disadvantagesEasy to compareResourcesFour quadrantsOutcome measures
The invention relates to a city development level calculation method. The method comprises the steps of obtaining city index data and establishing a city livable index database; obtaining a starting value and an ideal value of a city development level evaluation index and performing indexing processing; determining a weight of the city development level evaluation index; performing weighted calculation on the starting value and the ideal value, subjected to the indexing processing, of the city development level evaluation index to calculate a city construction process index value and an ecological construction result index value; and including a city in different quadrants of a two-dimensional plane rectangular coordinate system according to the city construction process index value and the ecological construction result index value, and determining a city development level according to the different quadrants where the city is located, wherein the starting value is a minimum value of the city development level evaluation index, and the ideal value is an optimal value of the city development level evaluation index. According to the method, the shortcomings of complexity and hugeness of a conventional index system are overcome, and the city development level is not only limited to simplex numerical ranking; and city ecological livable development results are represented by four quadrants, so that the city position can be clearly determined more quickly.
Owner:SHENZHEN INST OF BUILDING RES

Compositions and methods for inhibiting cell migration

InactiveUS7465585B1Dkk activity is elevatedDecrease Dkk activityPeptide/protein ingredientsBiological testingGood prognosisOutcome measures
The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt / β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt / β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.
Owner:BURNHAM INST THE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products